Completed PHASE3 INTERVENTIONAL 7-arm NCT00079274

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer

Sponsor: Eastern Cooperative Oncology Group

Conditions Adenocarcinoma of the Colon Stage III Colon Cancer

Interventions Locally Directed Therapy cetuximab fluorouracil irinotecan hydrochloride leucovorin calcium oxaliplatin

Updated 10 times since 2017 Last updated: Apr 28, 2020 Started: Feb 29, 2004 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00079274, this PHASE3 trial focuses on Adenocarcinoma of the Colon and Stage III Colon Cancer and remains completed. Sponsored by Eastern Cooperative Oncology Group, it has been updated 10 times since 2004, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

Jun 2020 — Jan 2021 [monthly]

Completed PHASE3
Jan 2019 — Jun 2020 [monthly]

Completed PHASE3
Jun 2018 — Jan 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Abington, United States , Adrian, United States , Akron, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Allentown, United States , Alton, United States , Amarillo, United States and 526 more locations